Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novavax, Inc. - Common Stock (NQ:NVAX)

7.760 +1.030 (+15.30%)
Streaming Delayed Price Updated: 11:34 AM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novavax, Inc. - Common Stock

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
62 63 Next >
Here's The Good News For Novavax Ahead Of Its Fourth-Quarter Report
Novavax is expected to report strong sales growth. But 2023 guidance will be key. 
Via Investor's Business Daily
2 Stocks to Sell or Remove From Your Watchlist in 2023
Both stocks soared during the coronavirus vaccine race, but their time has passed. 
Via The Motley Fool
Coronavirus Vaccine Market To Surpass $95 Billion By 2028
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:MRNA),(NASDAQ:NVAX),(NASDAQ:VIR),(NASDAQ:INO) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19
Nasdaq, S&P 500 Futures Flatline Ahead Of Housing, Consumer Data: Analyst Pins Hopes On Dollar, Fed Rates To Keep Flickering Rally Hopes Alive
Trading in the U.S. index futures suggests stocks may start Tuesday’s session slightly higher, although the mood could be cautious ahead of some key economic data on the housing market, business... 
Via Benzinga
Earnings Preview: Novavax
Via Benzinga
Why Novavax Stock Wilted on Wednesday
It doesn't seem like investors are looking forward to the company's fourth-quarter and full-year 2022 earnings release. 
Via The Motley Fool
Earnings Scheduled For February 28, 2023
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its fourth quarter. 
Via Benzinga
More Likely to 5x First: Novavax vs. Ocugen
They skyrocketed before. It could happen again. 
Via The Motley Fool
Here's the Worst Mistake Novavax Investors Can Make in 2023
Can Novavax still win over the long term? 
Via The Motley Fool
3 Supercharged Growth Stocks Down 89% to 97% That Billionaires Can't Stop Buying
Beaten-down growth stocks were popular buys during the fourth quarter for some of the brightest billionaire money managers. 
Via The Motley Fool
2 Beaten-Down Stocks That Might Be too Cheap to Ignore
There is an argument for hitting the buy button, but it's important to consider the potential risks too. 
Via The Motley Fool
Harmony Biosciences, The No. 3 Biotech, Just Topped Forecasts; But Concerns Persist
The company offered neither financial guidance nor plans for a new CEO. 
Via Investor's Business Daily
Is This the Telltale Sign to Sell Novavax Stock?
You won't find Novavax's latest bad news trumpeted in a press release. 
Via The Motley Fool
Why Is Monday.com (MNDY) Stock Up 11% Today?
Monday.com (MNDY) stock is on the rise Monday after announcing a partnership with Appfire to expand its app marketplace. 
Via InvestorPlace
NVAX Stock Alert: Novavax Will Provide 1.5 Million More Covid-19 Vaccine Doses to U.S.
Novavax (NVAX) stock is on the move Monday after extending its Covid-19 vaccine supply agreement with the U.S. government. 
Via InvestorPlace
These Cheap Growth Stocks Could Supercharge Your Portfolio
All of these players are cheap today considering their growth potential. 
Via The Motley Fool
Is Novavax Stock a Buy With the New Normal for COVID?
The landscape has shifted dramatically in the COVID-19 vaccine market. 
Via The Motley Fool
Better Buy: Novavax or BioNTech Stock?
The two companies, known for their vaccines, could see their businesses benefit from a yearly COVID-19 shot. 
Via The Motley Fool
MarketBeat Week in Review – 1/30 - 2/3
The markets are trending lower to end the week. It’s hard to figure out the markets after the blockbuster job report, but the MarketBeat team gave it a shot 
Via MarketBeat
Topics Artificial Intelligence Earnings Economy
Exposures Artificial Intelligence Financial Interest Rates
3 Sorry Pharma Stocks to Sell in February Before It’s Too Late
These are the pharma stocks to sell, as they represent companies with weak fundamentals and sustained cash burn visibility. 
Via InvestorPlace
Novavax Shares Jumped in January While Others Slipped
Updated FDA Covid vaccine policy could've boosted NVAX shares at the end of January, when other pharma stocks slipped, but it may not affect the bottom line. 
Via MarketBeat
Exposures COVID-19 Product Safety
1 Reason to Buy Novavax in 2023 and 2 Reasons to Sell
Novavax shares sank 93% last year. 
Via The Motley Fool
$1,000 Invested In 4 Of The 5 Vaccine Developers Back When WHO Declared COVID-19 An Emergency Yielded Returns
The COVID-19 pandemic emerged in 2019 in China and spread to the rest of the globe in early 2020. Since then, the virus has caused more than 6.8 million deaths. 
Via Benzinga
Novavax Jumps After Pledging To Update Its Covid Shot; Pfizer, Moderna Slip
The FDA's experts voted in favor of annual boosters on Thursday. 
Via Investor's Business Daily
3 Great Growth Stocks Down 20% or More to Buy Now
These beaten-down stocks could be poised for major rebounds. 
Via The Motley Fool
This Investment Strategy Would Have Reduced Your Novavax Losses by 20% Last Year
If you want to invest in volatile stocks, a certain strategy can minimize your overall risk. 
Via The Motley Fool
3 Remarkable Stocks That Can Burn Short-Sellers Big-Time in 2023
Exceptionally high short interest in these innovative and transformative businesses may lead to a short squeeze. 
Via The Motley Fool
Could Novavax Stock Help You Become a Millionaire?
At such a beaten-down valuation, is the upside for Novavax just too significant to ignore? 
Via The Motley Fool
River Private Wealth announces new round of investment in Novavax, Inc
Via AB Newswire
3 Biotech Stocks Under $15 Worth a Second Look in 2023
All three stocks have promising therapies that could drive revenue in the coming years. 
Via The Motley Fool
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
62 63 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.